Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2009.04.039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Rare Entity of Basaloid Thymic Carcinoma: A Multicentric Retrospective Analysis from the Italian Collaborative Group for ThYmic MalignanciEs (TYME).
Cancers (Basel)
January 2025
Medical Oncology Division, Humanitas Gavazzeni, 24125 Bergamo, Italy.
Background: thymic basaloid carcinoma (BTC) is an extremely rare tumor, and very little data are available on BTC's biology, clinical behavior, drug sensitivity, and patient outcomes.
Methods: We performed a retrospective observational study on patients diagnosed with BTC in 11 referral centers of TYME. All BTC diagnoses were reviewed by the referring pathologist.
High expression of cellular self-activated immunosuppressive molecules and extensive infiltration of suppressive immune cells in the tumor microenvironment are the main factors contributing to glioma's resistance to immunotherapy. Nonetheless, technology to modify the expression of glioma cellular self-molecules through gene editing requires further development. This project advances cell therapy strategies to reverse the immunosuppressive microenvironment of glioma (TIME).
View Article and Find Full Text PDFPropofol Triggers Cell Death in Lung Cancer Cells by Increasing PANX1 Expression, Activating the Mitochondrial Cell Death Pathway, and Enhancing ROS Levels.
Discov Med
November 2024
Anesthesiology and Perioperative Medicine Department, Shandong Public Health Clinical Center, 250000 Jinan, Shandong, China.
Background: Lung cancer treatment remains a global challenge due to tumor cell resistance. Propofol, traditionally used as an anesthetic, has demonstrated potential anti-tumor properties. This study seeks to elucidate how propofol induces cell death in lung cancer cells by upregulating Pannexin 1 (PANX1) expression, activating the mitochondrial cell death pathway, and augmenting reactive oxygen species (ROS) production.
View Article and Find Full Text PDFPretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation.
Cancer Immunol Immunother
November 2024
Department of Pancreatic-Biliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Immune checkpoint inhibitor (ICI)-based immunotherapy has emerged as the most promising strategy for hepatocellular carcinoma (HCC) downstaging prior to liver transplantation (LT). However, further evidence is required to assess the feasibility and safety of pretransplant ICI exposure. We retrospective analyzed 159 HCC patients who underwent LT at our institution from June 2019 to December 2023, and 39 recipients (39/159, 24.
View Article and Find Full Text PDFAcetylcysteine synergizes PD-1 blockers against colorectal cancer progression by promoting TCF1PD1CD8 T cell differentiation.
Cell Commun Signal
October 2024
Department of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Background: Programmed cell death protein 1 (PD-1) blockade is essential in treating progressive colorectal cancer (CRC). However, some patients with CRC do not respond well to immunotherapy, possibly due to the exhaustion of CD8 T cells in the tumor microenvironment. N-Acetylcysteine (NAC) can reduce CD8 T cell exhaustion in vitro and induce their differentiation into long-lasting phenotypes, thus enhancing the anti-tumor effect of adoptive T cell transfer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!